- Home
- BYSI vs PRLD Comparison
BYSI vs PRLD Comparison
Compare BYSI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- PRLD
- Stock Information
- Founded
- BYSI 2010
- PRLD 2016
- Country
- BYSI United States
- PRLD United States
- Employees
- BYSI N/A
- PRLD N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- BYSI Health Care
- PRLD Health Care
- Exchange
- BYSI Nasdaq
- PRLD Nasdaq
- Market Cap
- BYSI 72.1M
- PRLD 73.7M
- IPO Year
- BYSI 2017
- PRLD 2020
- Fundamental
- Price
- BYSI $1.79
- PRLD $0.87
- Analyst Decision
- BYSI
- PRLD Strong Buy
- Analyst Count
- BYSI 0
- PRLD 2
- Target Price
- BYSI N/A
- PRLD $4.50
- AVG Volume (30 Days)
- BYSI 10.8K
- PRLD 196.9K
- Earning Date
- BYSI 01-01-0001
- PRLD 03-04-2025
- Dividend Yield
- BYSI N/A
- PRLD N/A
- EPS Growth
- BYSI N/A
- PRLD N/A
- EPS
- BYSI N/A
- PRLD N/A
- Revenue
- BYSI $1,876,000.00
- PRLD $3,000,000.00
- Revenue This Year
- BYSI N/A
- PRLD N/A
- Revenue Next Year
- BYSI N/A
- PRLD N/A
- P/E Ratio
- BYSI N/A
- PRLD N/A
- Revenue Growth
- BYSI 21.03
- PRLD N/A
- 52 Week Low
- BYSI $1.05
- PRLD $0.80
- 52 Week High
- BYSI $4.00
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- BYSI 56.87
- PRLD 37.59
- Support Level
- BYSI $1.61
- PRLD $0.87
- Resistance Level
- BYSI $1.88
- PRLD $1.01
- Average True Range (ATR)
- BYSI 0.10
- PRLD 0.08
- MACD
- BYSI 0.00
- PRLD -0.02
- Stochastic Oscillator
- BYSI 66.67
- PRLD 0.90
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.